- Home
- TENX vs CMMB Comparison
TENX vs CMMB Comparison
Compare TENX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- CMMB
- Stock Information
- Founded
- TENX 1967
- CMMB 2004
- Country
- TENX United States
- CMMB Israel
- Employees
- TENX N/A
- CMMB N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- CMMB Health Care
- Exchange
- TENX Nasdaq
- CMMB Nasdaq
- Market Cap
- TENX 21.6M
- CMMB 23.0M
- IPO Year
- TENX N/A
- CMMB N/A
- Fundamental
- Price
- TENX $5.83
- CMMB $1.16
- Analyst Decision
- TENX Strong Buy
- CMMB Strong Buy
- Analyst Count
- TENX 3
- CMMB 2
- Target Price
- TENX $16.00
- CMMB $8.50
- AVG Volume (30 Days)
- TENX 41.0K
- CMMB 182.4K
- Earning Date
- TENX 08-12-2025
- CMMB 08-20-2025
- Dividend Yield
- TENX N/A
- CMMB N/A
- EPS Growth
- TENX N/A
- CMMB N/A
- EPS
- TENX N/A
- CMMB N/A
- Revenue
- TENX N/A
- CMMB N/A
- Revenue This Year
- TENX N/A
- CMMB N/A
- Revenue Next Year
- TENX N/A
- CMMB N/A
- P/E Ratio
- TENX N/A
- CMMB N/A
- Revenue Growth
- TENX N/A
- CMMB N/A
- 52 Week Low
- TENX $2.80
- CMMB $0.87
- 52 Week High
- TENX $7.89
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- TENX 50.54
- CMMB 38.60
- Support Level
- TENX $5.68
- CMMB $1.17
- Resistance Level
- TENX $5.98
- CMMB $1.20
- Average True Range (ATR)
- TENX 0.39
- CMMB 0.05
- MACD
- TENX 0.00
- CMMB 0.00
- Stochastic Oscillator
- TENX 18.87
- CMMB 16.46
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.